What's new in non-small cell lung cancer forpathologists: The importance of accurate subtyping, EGFR mutations and ALK rearrangements

Pathology

Volumn 43, Issue 2, 2011, Pages 103-115

  Cooper, Wendy A ^a,c   O'toole, Sandra ^a,d,e,f   Boyer, Michael ^b,d   Horvath, Lisa ^b,d   Mahar, Annabelle ^a  

^a Departments of Tissue Pathology and Diagnostic Oncology   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adenocarcinoma; ALK; Diagnosis; Epidermal growth factor receptor; FISH; Immunohistochemistry; Non small cell lung cancer; NSCLC subtype; Protein tyrosine kinases; Small biopsy; Squamous cell carcinoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADENOCARCINOMA; ALGORITHM; DIFFERENTIAL DIAGNOSIS; GENE REARRANGEMENT; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; PROTO ONCOGENE; REVIEW; SQUAMOUS CELL CARCINOMA; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; GENE REARRANGEMENT; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 79955974560     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328342629d     Document Type: Review

References (127)

1. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia 2001. Canberra: AIHW; 2004.
2. Travis WD, Rekhtman N, Riley GJ, et al.Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology. J Thorac Oncol 2010; 5: 411-4.
3. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization Classification of Tumours.pathology and Genetics of Tumours of the Lung,pleura, Thymus and Heart. Lyon: IARCpress; 2004.
4. Tam IYS, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutationpatterns in non small cell lung cancerpatients with different tobacco exposure and clinicoPathologic features. Clin Cancer Res 2006; 12: 1647-53.
5. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expressionprofiling reveals distinct adenocarcinoma subclasses.Proc Natl Acad Sci USA 2001; 98: 13790-5. (Pubitemid 33115977)
6. Takeuchi T, Tomida S, Yatabe Y, et al. Expressionprofile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicoPathologic behaviors. J Clin Oncol 2006; 24: 1679-88. (Pubitemid 46622139)
7. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenancepemetrexedplus best supportive care versusplaceboplus best supportive care for nonsmall- cell lung cancer: a randomised, double-blind,phase 3 study. Lancet 2009; 374: 1432-40.
8. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy ofpemetrexed according to NSCLC histology: a review of twophase III studies. Oncologist 2009; 14: 253-63.
9. Scagliotti GV,Parikh P, vonpawel J, et al.Phase III study comparing cisplatinplus gemcitabine with cisplatinpluspemetrexed in chemotherapy- naivepatients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
10. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomizedphase II trial comparing bevacizumabplus carboplatin andpaclitaxel with carboplatin andpaclitaxel alone inpreviously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91. (Pubitemid 41095154)
11. Mok TS, Wu Y, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel inpulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
12. Horn L,pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009; 27: 4232-5.
13. Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7Hpyrrolo[2, 3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992; 35: 4450-4.
14. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L,papotti M. Theprognostic andpredictive role of histology in advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 1468-81.
15. Petersonp,Park K, Fossella F, Gatzemeier U, John W, Scagliotti G. Ispemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of aphase III trial ofpemetrexed vs docetaxel inpreviously treatedpatients with advanced non-small cell lung cancer (NSCLC):p2-328. J Thorac Oncol 2007; 2: S851.
16. Scagliotti G,purvishp, vonpawel J, et al.Phase III study ofpemetrexedplus cisplatin versus gemcitabineplus cisplatin in chemonaivepatients with locally advanced or metastatic non-small cell lung cancer (NSCLC):pRS-03. J Thorac Oncol 2007; 2: S306.
17. Ceppip, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA andprotein levels for thymidylate synthase. Cancer 2006; 107: 1589-96. (Pubitemid 44546920)
18. Giovannetti E, Mey V, Nannizzi S, et al. Cellular andpharmacogenetics foundation of synergistic interaction ofpemetrexed and gemcitabine in human non-small-cell lung cancer cells. Molpharmacol 2005; 68: 110-8. (Pubitemid 41002949)
19. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76. (Pubitemid 36749215)
20. Reck M, vonpawel J, Zatloukalp, et al.Phase III trial of cisplatinplus gemcitabine with eitherplacebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27: 1227-34.
21. Sandler A, Gray R,perry MC, et al.paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50. (Pubitemid 44917502)
22. Grilley-Olson JE, Hayes DN, Qaqish BF, et al. Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed nonsmall cell lung cancer (NSCLC) chemotherapy: A largeprospective study. J Clin Oncol 2009; 27: S409; (abstr).
23. Field RW, Smith BJ,platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004; 96: 1105-7. (Pubitemid 39172413)
24. Stang A,pohlabeln H, Muller KM, Jahn I, Giersiepen K, Jockel KH. Diagnostic agreement in the histoPathological evaluation of lung cancer tissue in apopulation-based case-control study. Lung Cancer 2006; 52: 29-36. (Pubitemid 43340196)
25. Vinod SK, O'Connell DL, Simonella L, et al. Gaps in optimal care for lung cancer. J Thorac Oncol 2008; 3: 871-9.
26. Edwards SL, Roberts C, McKean ME, et al.preoperative histological classification ofprimary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clinpathol 2000; 53: 537-40. (Pubitemid 30432112)
27. Nicholson AG, Gonzales D, Shahp, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytological material, using apanel of mucin staining, TTF-1, cytokeratin 5/6, andp63, and EGFR mutation analysis. J Thorac Oncol 2010; 5: 436-41.
28. Roggli VL, Vollmer RT, Greenberg SD, et al. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol 1985; 16: 569-79. (Pubitemid 15049631)
29. Travis WD, Garg K, Franklin WA, et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004World Health OrganizationPathologic criteria. J Thorac Oncol 2006; 1: S13-9. (Pubitemid 47181353)
30. Barlesi F,pinot D, Legoffic A, et al.positive thyroid transcription factor 1 staining strongly correlates with survival ofpatients with adenocarcinoma of the lung. Br J Cancer 2005; 93: 450-2. (Pubitemid 43080019)
31. Johansson L. HistoPathological classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagnpathol 2004; 8: 259-67. (Pubitemid 39370567)
32. Kalhor N, Zander DS, Liu J. TTF-1 andp63 for distinguishingpulmonary small cell carcinoma frompoorly differentiated squamous cell carcinoma inpreviouslypAP stained cytological material. Mod pathol 2006; 19: 1117-23. (Pubitemid 44106727)
33. Sturm N, Lantuujoul S, Laverriere MH, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14(34bE12) expression in basaloid and largecell neuroendocrine carcinomas of the lung. Hum Pathol 2001; 32: 918-25. (Pubitemid 32911313)
34. Tan D, Li O, Deeb G, et al. Thyroid transcription factor-1 expressionprevalence and its clinical implications in non-small cell lung cancer: a high throughput tissue microarray and immunohistochemical study. Hum Pathol 2003; 34: 597-604. (Pubitemid 36750372)
35. Au NH, Gown AM, Cheang M, et al.p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004; 12: 240-7.
36. Camilo R, Capelozzi VL, Siqueira SAC, Bernardi FDC. Expression ofp63, keratin 5/6, keratin 7 and surfactant-A in non-small cell carcinoma. Hum Pathol 2006; 37: 542-6.
37. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker forpulmonary adenocarcinomas and large cell carcinomas compared to surfactantproteins A and B. Histopathology 2000; 36: 8-16. (Pubitemid 30055417)
38. Pelosi G, Fraggetta F,pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surgpathol 2001; 25: 363-72. (Pubitemid 32175139)
39. Stenhouse G, Fyfe N, King G, et al. Thyroid transcription factor 1 inpulmonary adenocarcinoma. J Clinpathol 2004; 57: 383-7. (Pubitemid 38446256)
40. Yatabe Y, Mitsudomi T, Takahashi T, et al. TTF-1 expression inpulmonary adenocarcinomas. Am J Surgpathol 2002; 26: 767-72.
41. LoopSL, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010; 5: 442-7.
42. Liu J, Farhood A. Immunostaining for thyroid transcription factor-1 on fine-needle aspiration specimens of lung tumours. Cancer Cytopathol 2004; 102: 109-14.
43. Kerr KM.pulmonary adenocarcinomas: classification and reporting. Histopathology 2009; 54: 12-27.
44. Downeyp, Cummins R, Moran M, Gulmann C. If it's not CK5/6positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS 2008; 116: 526-9.
45. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK5/6 andp63 immunostaining in classification of lung carcinomas. Mol Morphol 2007; 15: 415-20. (Pubitemid 350307847)
46. Kaufmann O, Fietze E, Mengs J, et al. Value ofp63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis ofpoorly differentiated and undifferentiated carcinomas. Am J Clinpathol 2001; 116: 823-30. (Pubitemid 33108152)
47. Jorda M, Gomez-Fernandez C, Garcia M, et al.p63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer Cytopathol 2009; 117: 46-50.
48. Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34bE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clinpathol 2004; 122: 884-93. (Pubitemid 39577356)
49. Motoi N, Szoke H, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histology subtype suggests correlations betweenpapillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surgpathol 2008; 32: 810-27.
50. Kerr KM, Fyfe MN, Nicolson MC, et al. Influence of tumourpatterns in mixed-type adenocarcinoma onpost-operative survival. J Thorac Oncol 2007; 2: S801-2.
51. Riquet M, Foucault C, Bernap, et al.prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg 2006; 81: 1988-95. (Pubitemid 43775587)
52. Aida S, Shimazaki H, Sato K, et al.prognostic analysis ofpulmonary adenocarcinomas subclassification with special consideration ofpapillary and bronchioloalveolar types. Histopathology 2004; 45: 468-76. (Pubitemid 39524321)
53. Yokose T, Suzuki K, Nagai K, et al. Favourable and unfavourable morphologicalprognostic factors inperipheral lung adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer 2000; 29: 179-88.
54. Miyoshi T, Satoh Y, Okumura S, et al. Early-stage lung adenocarcinomas with a micropapillarypattern, a distinctPathologic marker for a significantlypoorprognosis. Am J Surgpathol 2003; 27: 101-9. (Pubitemid 36014903)
55. Travis WD, Brambilla E, Noguchi M, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2009; 4: S86-9; (abstr).
56. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci USA 2004; 101: 13306-11. (Pubitemid 39209661)
57. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39. (Pubitemid 38637993)
58. Paez JG, JannepA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. (Pubitemid 38720929)
59. Riely GJ,politi KA, Miller VA,paoW. Update on epidermal growth factor receptor mutations in non small cell lung cancer. Clin Cancer Res 2006; 12: 7232-41. (Pubitemid 46095394)
60. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype,predict response to erlotinib. J Clin Oncol 2008; 26: 1472-8.
61. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005; 11: 5878-85. (Pubitemid 41170316)
62. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicoPathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11: 1167-73. (Pubitemid 40175767)
63. van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- andprospective observations in non-small-cell lung cancer. Ann Oncol 2007; 18: 99-103. (Pubitemid 46152507)
64. BunnpA, Dziadziuszko R, Varella-Garcia M, et al. Biological markers for non-small cell lung cancerpatient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 2006; 12: 3652-6. (Pubitemid 44000246)
65. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
66. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatinplus docetaxel inpatients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomisedphase 3 trial. Lancet Oncol 2010; 11: 121-8.
67. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4- anilinoquinazoline inhibitor. J Biol Chem 2002; 277: 46265-72.
68. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009; 15: 1133-9.
69. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J Natl Cancer Inst 2005; 97: 339-46. (Pubitemid 40425952)
70. Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-27. (Pubitemid 46349842)
71. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.pLoS Med 2005; 2: 313.
72. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92. (Pubitemid 40271173)
73. Shih J-Y, Gow C-H, Yangp-C. EGFR mutation conferringprimary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med 2005; 353: 207-8. (Pubitemid 41058355)
74. Balak MN, Gong Y, Riely GJ, et al. Novel D761Yand common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12: 6494-501. (Pubitemid 44799723)
75. Bean J, Brennan C, Shih J-Y, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.Proc Natl Acad Sci 2007; 104: 20932-7.
76. Turke AB, Zejnullahu K,Wu Y, et al.preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
77. Blons H, Cote J, Le Corre D, et al. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surgpathol 2006; 30: 1309-15. (Pubitemid 44454711)
78. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS arepredictive andprognostic indicators inpatients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-9.
79. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening withpotential implications onpharmacologic treatment. J Clin Oncol 2005; 23: 857-65. (Pubitemid 46224186)
80. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-67.
81. Tsao AS, Tang XM, Sabloff B, et al. ClinicoPathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006; 1: 231-9. (Pubitemid 47181440)
82. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005; 11: 2106-10. (Pubitemid 40490166)
83. Hsieh R-K, Lim K-H, Kuo H-T, Tzen C-Y, Huang M-J. Female sex and bronchioloalveolarPathologic subtypepredict EGFR mutations in nonsmall cell lung cancer. Chest 2005; 128: 317-21. (Pubitemid 40994490)
84. Wu Y, Zhong W, Li L, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy inpatients with non-small cell lung cancer: a meta-analysis based on updated individualpatient data from six medical centers in mainland China. J Thorac Oncol 2007; 2: 430-9. (Pubitemid 47181698)
85. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification IDEAL INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-92.
86. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect keypathways in lung adenocarcinoma. Nature 2008; 455: 1069-75.
87. Sequist LV, Joshi V, JannepA, et al. Epidermal growth factor receptor mutation testing in the care of lung cancerpatients. Clin Cancer Res 2006; 12: S4403-8.
88. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surgpathol 2005; 29: 633-9. (Pubitemid 40577873)
89. Dacic S. EGFR assays in lung cancer. Adv Anatpathol 2008; 15: 241-7.
90. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib inpatients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-9.
91. Haneda H, Sasaki H, Lindeman N, et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanesepatients with adenocarcinoma. Japan J Clin Oncol 2006; 36: 69-75.
92. Sartori G, Cavazza A, Sgambato A, et al. EGFR and K-ras mutations along the spectrum ofpulmonary epithelial tumors of the lung and elaboration of a combined clinicoPathologic and molecular scoring system topredict clinical responsiveness to EGFR inhibitors. Am J Clinpathol 2009; 131: 478-89.
93. Jiang SX, Yamashita K, Yamamoto M, et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer 2008; 123: 2480-6.
94. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation andpresence of KRAS mutation in lung adenocarcinomas and bronchioloalveolar features. J Mol Diagn 2007; 9: 320-6. (Pubitemid 47305068)
95. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillarypattern and the hobnail cell type. Lung Cancer 2009; 63: 235-40.
96. Miller VA, Kris MG, Shah N, et al. BronchioloalveolarPathologic subtype and smoking historypredict sensitivity to gefitinib in advanced non-smallcell lung cancer. J Clin Oncol 2004; 22: 1103-9. (Pubitemid 41095044)
97. Kim YH, Ishii G, Goto K, et al. Dominantpapillary subtype is a significantpredictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004; 10: 7311-7. (Pubitemid 39487720)
98. Achcar R, Nikiforova MN, Yousem SA. Micropapillary lung adenocarcinoma. Am J Clinpathol 2009; 131: 694-700.
99. Oxnard GR, Miller VA. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology 2010; 24: 392-9.
100. Pirker R, Herth JF, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer. Results from a European Workshop. J Thorac Oncol 2010; 5: 1706-13.
101. Garcia-Olive I, Monso E, Andreo F, et al. Endobronchial ultrasoundguided transbronchial needle aspiration for identifying EGFR mutations. Eur Resp J 2010; 35: 391-5.
102. Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 2008; 98: 154-60.
103. Schuurbiers OCJ, Looijen-Salamon MG, Ligtenberg MJL, van der Heijden HFM. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010; 5: 1664-7.
104. Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a betterpredictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clinpathol 2010; 133: 922-34.
105. Kato Y,Peled N, Wynes M, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as apossible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010; 5: 1551-8.
106. Yu J, Kane S,Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small cell lung cancer. Clin Cancer Res 2009; 15: 3023-8.
107. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010; 16: 3349-55.
108. Nakano H, Soda H, Takasu M, et al. Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 2008; 60: 136-40. (Pubitemid 351434456)
109. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008; 99: 929-35. (Pubitemid 351997594)
110. Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptorpathway betweenprimary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009; 4: 809-15.
111. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status betweenprimary tumours and corresponding metastases in NSCLC. Br J Cancer 2008; 99: 923-9.
112. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008; 68: 3389-95.
113. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009; 420: 345-61.
114. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6. (Pubitemid 47206930)
115. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-83.
116. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALKpositive lung cancer.Proc Natl Acad Sci 2008; 105: 19893-7.
117. Solomon B, Varella-garcia M, Camidge DR. ALK gene rearrangements. A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009; 4: 1450-4.
118. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16: 1561-71.
119. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009; 40: 1152-8.
120. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008; 3: 13-7.
121. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174: 661-70.
122. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicoPathologic features characterize ALK-rearranged lung adenocarcinoma in the Westernpopulation. Clin Cancer Res 2009; 15: 5216-23.
123. Sakairi Y, Nakajima T, Yasufuku K, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 2010; 16: 4938-45.
124. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-9.
125. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome ofpatients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-53.
126. Takahashi T, Sonobe M, Kobayashi M, et al. ClinicoPathologic features of non-small cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010; 17: 889-97.
127. Wong DW, Leung EL, So KK-T, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115: 1723-33.